Miniaturized Bioassay System Expected To Lower Drug Development Costs

A miniaturized bioassay platform that is expected to enable less expensive and more efficient compound screening has become available to drug developers.

The technology behind the DropArray system was developed by the Institute of Bioengineering and Nanotechnology (Singapore). The instrument exploits a microfluidic method that reduces the amounts of materials and reagents required to conduct a cell-based assay by a factor of 1,000 and reduces the reaction time by a factor of 10. Thus, a sample volume as small as 100 nl may be tested instead of the 50 to 100 µl required by other instruments.


3D Tissue Models
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.